The federal government on Tuesday urged the judges in AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ separate 340B contract pharmacy lawsuits to follow the lead of the judge in Lilly’s case and hold that these five companies’ contract pharmacy policies are illegal.
Novo Nordisk and Sanofi, meanwhile, on Nov. 2 asked the judge who is assigned to both of their cases to let them file supplemental briefs addressing the Oct. 29 ruling in Lilly’s case. That judge, Freda Wolfson of U.S. District Court in Trenton, N.J., said last month she would hand down her decision on Sanofi’s case on or before tomorrow, Nov. 5. While Wolfson has never said that she also will hand down her ruling in Novo Nordisk’s case on or before tomorrow, she could.
The federal government on Tuesday urged the judges in AstraZeneca, Novartis, Novo Nordisk, Sanofi, and United Therapeutics’ separate 340B contract pharmacy lawsuits to follow the lead of the judge in Lilly’s case and hold that these five companies’ contract pharmacy policies are illegal.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
